Lannett (LCI) – Lawsuits Will Wipe Out The Equity" Citron ResearchGuest Post
If Even Modest Price Cuts Hit Either of Lannett’s Cash Cow Drugs, It Will Violate Its Debt Covenants
$13-$15 Near Term Target
Equity Worthless Over Long-Term
Over the past year, almost every media outlet in the US has dissected the pharmaceutical industry to expose the culprits of rampant opportunistically driven price gouging. We are . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email email@example.com and we will get back to you as quick as humanly possible